Norwegian version of this page

Molecular characterization of tumour tissue and liquid biopsies

Since protein expression is more directly representative of functional changes in tumour cells compared to other molecular levels, we envision that robust targets for patient stratification can be identified by analysis of changes in protein expression.

We hypothesize that combining transcriptomics and proteomics analyses will unveil regulatory mechanisms of cellular functions and pathways that are important for disease development, that is, mechanisms that may not be apparent at a single molecular level.

We perform experimental methods and computational analyses of molecular data derived from tumor biopsies, patient-derived xenograft cell lines and liquid biopsies. The data will be used in drug screening to explore how treatment response is linked to subtypes.

Another aim is to uncover the link between biological pathways of clinical interest including the rewired metabolic program in the tumours and the circulating metabolite profiles. We will explore the clinical relevance of plasma-circulating cell-free DNA in patients with primary resectable, borderline and locally advanced (i.e., NorPACT-2 and NorPACT-3 clinical studies) and metastatic pancreatic cancer (in collaboration with work packages "Surgery" and "Circulating tumour DNA").

Molecular data will also be correlated with morphological heterogeneity of the tumour (in collaboration with work package "Pathology").

Collaborators

  • Knut Jørgen Labori (work package «Surgery»), OUH/UiO
  • Caroline Verbeke (work package «Pathology»), UiO/OUH
  • Kjetil Tasken (work package «Drug screening»), OUH/UiO
  • Oddmund Nordgård (work package «Circulating tumour DNA»), SUH
  • Janne Lethio (Proteomics), Karolinska Institutet
  • Bjørn Skålhegg (Metabolism, amino acid profiles), UiO
  • Gry Aarum Geitvik (Liquid biopsies), OUH
  • Ole Christian Lingjærde (Statistics), UiO

 

Published Mar. 1, 2021 3:59 PM - Last modified Feb. 24, 2023 4:58 PM